Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor
who has a CMV response to the peptivators will be screened.
All patients will receive treatment with valganciclovir or ganciclovir. There is a safety run
in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2
for randomization to receive antiviral therapy with or without CMV CTLs.